Compare StocksAXP vs REGN

American Express Company (AXP) vs Regeneron Pharmaceuticals, Inc. (REGN): Which Is the Better Buy in 2026?

As of 2026-06-19, AXP is undervalued at $338, with a DCF intrinsic value of $484 and a margin of safety of 30%. REGN is undervalued at $610, with an intrinsic value of $1572 and a margin of safety of 61%. Of the two, REGN has the wider margin of safety.

AXP
American Express Company
$338.00
VS
REGN
Regeneron Pharmaceuticals, Inc.
$609.94

Rewards

AXP
  • Gross margin of 62.8% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • American Express Company scores 100/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.
  • Return on equity has consistently exceeded 20% over 4 years, indicating efficient use of shareholder capital.
REGN
  • Regeneron Pharmaceuticals, Inc. scores 80/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.
  • Trailing P/E of 14.9x is 22% below the historical average of 19.2x — potentially undervalued relative to its own history.
  • Altman Z-Score of 7.56 indicates very low bankruptcy risk — the company is firmly in the safe zone.

Risks

AXP
  • Altman Z-Score of 0.93 places the company in the distress zone — financial patterns resemble those of companies that experienced bankruptcy.
  • 17 insider sales with no purchases over the past 12 months — a persistent pattern of insider selling.
  • Free cash flow has declined at a 5.9% CAGR over the past 4 years — a concerning trend.
REGN
  • ROIC has declined by 7.3 percentage points over the past 4 years, which may signal competitive erosion.
  • Each dollar of retained earnings has produced only $0.15 of earning power — shareholders may have been better served by dividends.
  • FCF yield of 5.1% suggests reasonable valuation assuming continued moderate growth.

Key Valuation Metrics

Learn more →
AXP
REGN
Valuation
N/A
Free Cash Flow
$3.27B
N/A
FCF Yield
5.12%
21.11
Trailing P/E
14.90
16.77
Forward P/E
11.34
Quality & Moat
12.23%
ROIC
7.13%
34.42%
ROE
14.55%
62.76%
Gross Margin
43.89%
1.62
PEG Ratio
1.07
Balance Sheet Safety
0.19
Net Debt / Equity
Net cash
N/A
Interest Coverage
N/A
N/A
Net Debt / EBITDA
-1.38
1.12%
Dividend Yield
0.61%
AXP: 4Ties: 1REGN: 4
AXPREGN

Historical Fundamentals

Learn more →
AXP

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

REGN

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
AXP
$6.18
created per $1 retained over 3 years
Exceptional Value Creator
Σ Retained
$23.29B
Δ Market Cap
+$144.01B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
REGN
$0.20
created per $1 retained over 3 years
Value Destroyer
Σ Retained
$12.50B
Δ Market Cap
+$2.52B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
AXP
30.1% Margin of Safety
Price is 30.1% below estimated fair value
Current Price: $338.00
Fair Value: $483.58
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
REGN
61.2% Margin of Safety
Price is 61.2% below estimated fair value
Current Price: $609.94
Fair Value: $1572.11
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
AXP

Requires positive FCF to compute implied growth rate.

REGN

What growth rate is the market pricing in at $610?

+1.6%
Market-Implied Owner Earnings Growth
Standard FCF implies +6.0%

The market implies +1.6% Owner Earnings growth, roughly in line with history — reasonably priced.

Standard FCF implies +6.0%, reflecting ongoing growth investment.

Economic Moat Score

Learn more →
AXP
100/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat driven primarily by revenue predictability. Margin Stability is the area most vulnerable to competitive pressure.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
REGN
80/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Revenue Predictability is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

Forensic Accounting

Learn more →
AXP
-2.51
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
REGN
-2.51
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
AXP
Insiders 22.3%Institutions 65.3%Retail & Other 12.3%
No. of Institutional Holders3,664
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
REGN
Insiders 2.0%Institutions 92.3%Retail & Other 5.6%
No. of Institutional Holders1,990
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
AXP
0
Buys (3M)
0
Buys (12M)
JOABAR RAYMOND D
Officer
$4,054
@ $176.26 · 2025-04-09
ANGELAKIS MICHAEL J
Director
$998,593
@ $269.89 · 2025-03-07
Open market purchases · includes direct & indirect ownership · excludes option exercises
REGN
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
AXP
0
Sells (3M)
17
Sells (12M)
Total value (12M): $145.68M
LIEBERMAN QUINN JESSICA
Officer
$909,661
@ $300.02 · 2026-03-06
JOABAR RAYMOND D
Officer
$4.77M
@ $340.67 · 2026-02-19
GROSFIELD HOWARD M
Officer
$2.82M
@ $346.73 · 2026-02-12
RADHAKRISHNAN RAVIKUMAR S
Chief Technology Officer
$5.35M
@ $356.58 · 2026-02-09
SEEGER LAUREEN E
Officer
$4.60M
@ $360.99 · 2026-02-09
MARRS ANNA
Officer
$9.60M
@ $350.01 · 2026-02-05
PICKETT DENISE
Officer
$8.35M
@ $356.91 · 2026-02-05
JOABAR RAYMOND D
Officer
$538,902
@ $384.93 · 2025-12-12
RUTLEDGE ELIZABETH
Officer
$18.01M
@ $360.21 · 2025-10-31
TABISH DOUGLAS J
Officer
$894,359
@ $355.61 · 2025-10-23
PICKETT DENISE
Officer
$1.75M
@ $350.73 · 2025-10-22
SQUERI STEPHEN J
Chief Executive Officer
$37.03M
@ $329.86 · 2025-09-04
HERENA MONIQUE
Officer
$2.83M
@ $325.88 · 2025-09-03
BUCKMINSTER DOUGLAS E
Officer
$7.67M
@ $326.37 · 2025-09-02
SEEGER LAUREEN E
Officer
$23.37M
@ $296.90 · 2025-08-06
MARRS ANNA
Officer
$1.71M
@ $310.77 · 2025-07-29
MCNEAL GLENDA G
Officer
$15.47M
@ $309.50 · 2025-07-29
MARQUEZ RAFAEL
Officer
$3.56M
@ $296.93 · 2025-05-20
GROSFIELD HOWARD M
Officer
$2.60M
@ $275.50 · 2025-05-06
MCNEAL GLENDA G
Officer
$799,009
@ $264.66 · 2025-04-29
MARRS ANNA
President
$6.32M
@ $287.88 · 2025-03-04
LIEBERMAN QUINN JESSICA
Officer
$897,590
@ $296.43 · 2025-02-26
MCNEAL GLENDA G
Officer
$2.29M
@ $309.96 · 2025-02-11
SQUERI STEPHEN J
Chief Executive Officer
$16.24M
@ $319.45 · 2025-02-06
RADHAKRISHNAN RAVIKUMAR S
Chief Technology Officer
$3.03M
@ $319.17 · 2025-02-05
JOABAR RAYMOND D
Officer
$3.53M
@ $317.01 · 2025-02-05
PICKETT DENISE
Officer
$7.25M
@ $318.69 · 2025-02-05
JOABAR RAYMOND D
Officer
$4.77M
@ $313.94 · 2025-01-28
LE CAILLEC CHRISTOPHE
Chief Financial Officer
$1.82M
@ $303.48 · 2024-11-27
HERENA MONIQUE
Officer
$374,010
@ $287.70 · 2024-11-07
SQUERI STEPHEN J
Chief Executive Officer
$48.90M
@ $286.57 · 2024-11-07
BUCKMINSTER DOUGLAS E
Officer
$3.55M
@ $270.98 · 2024-10-29
WILLIAMS ANRE D.
Officer
$21.05M
@ $270.26 · 2024-10-22
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
REGN
2
Sells (3M)
10
Sells (12M)
Total value (12M): $9.47M
RYAN ARTHUR F
Director
$70,524
@ $705.24 · 2026-05-01
RYAN ARTHUR F
Director
$77,727
@ $777.27 · 2026-04-01
RYAN ARTHUR F
Director
$78,550
@ $785.50 · 2026-03-02
ZOGHBI HUDA Y
Director
$1.28M
@ $781.33 · 2026-02-19
RYAN ARTHUR F
Director
$77,853
@ $778.53 · 2026-02-09
PITOFSKY JASON
Officer
$1.59M
@ $778.52 · 2026-02-09
BASSLER BONNIE L
Director
$1.20M
@ $800.00 · 2026-01-07
BASSLER BONNIE L
Director
$570,000
@ $750.00 · 2025-11-20
PITOFSKY JASON
Officer
$280,766
@ $651.43 · 2025-11-07
POON CHRISTINE A
Director
$4.25M
@ $654.27 · 2025-10-29
MCCOURT MARION E
Officer
$844,610
@ $844.61 · 2024-11-01
RYAN ARTHUR F
Director
$104,878
@ $1048.78 · 2024-10-01
MCCOURT MARION E
Officer
$1.05M
@ $1054.06 · 2024-10-01
RYAN ARTHUR F
Director
$117,868
@ $1178.68 · 2024-09-03
MCCOURT MARION E
Officer
$1.18M
@ $1178.73 · 2024-09-03
POON CHRISTINE A
Director
$12.55M
@ $1158.17 · 2024-08-15
BASSLER BONNIE L
Director
$884,520
@ $1170.00 · 2024-08-15
MURPHY ANDREW J
Officer
$7.34M
@ $1153.15 · 2024-08-14
STAHL NEIL E
Officer
$5.64M
@ $1084.54 · 2024-08-08
PITOFSKY JASON
Officer
$521,090
@ $1070.00 · 2024-08-07
BASSLER BONNIE L
Director
$842,940
@ $1115.00 · 2024-08-02
RYAN ARTHUR F
Director
$107,467
@ $1085.53 · 2024-08-01
RYAN ARTHUR F
Director
$1,100
@ $1100.00 · 2024-08-01
MCCOURT MARION E
Officer
$1.21M
@ $1060.86 · 2024-08-01
LAROSA JOSEPH J
General Counsel
$2.03M
@ $1088.95 · 2024-07-11
RYAN ARTHUR F
Director
$105,924
@ $1059.24 · 2024-07-01
MCCOURT MARION E
Officer
$1.19M
@ $1047.11 · 2024-07-01
BASSLER BONNIE L
Director
$802,872
@ $1062.00 · 2024-06-24
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
AXP
FearGreed
😐Neutral(58/100)

"Market is pricing this stock without strong emotion in either direction"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
REGN
FearGreed
😐Neutral(43/100)

"Market is pricing this stock without strong emotion in either direction"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
AXP
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Neutral (58)
REGN
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Neutral (43)
View AXP Full AnalysisView REGN Full Analysis

Frequently Asked Questions: AXP vs REGN

Is American Express Company or Regeneron Pharmaceuticals, Inc. more undervalued in 2026?

Based on our discounted cash flow model, REGN trades at a 61.2% margin of safety (intrinsic value $1572 vs. price $610), compared to AXP's 30.1% margin of safety (intrinsic $484 vs. $338).

Which stock has a wider economic moat, American Express Company or Regeneron Pharmaceuticals, Inc.?

AXP scores 100/100 (Wide moat), while REGN scores 80/100 (Wide moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is American Express Company in financial distress?

AXP's Altman Z-Score of 0.9 places it in the Distress zone, signaling elevated bankruptcy risk. REGN scores 7.6 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which stock has higher return on invested capital, American Express Company or Regeneron Pharmaceuticals, Inc.?

AXP earns 12.2% ROIC versus REGN's 7.1%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, American Express Company's or Regeneron Pharmaceuticals, Inc.'s?

AXP's dividend earns a safety score of 94/100 (Very Safe), compared to REGN's 85/100 (Very Safe). AXP has raised its dividend for 3 consecutive years.